Shin Jessica, Monti Stefano, Aires Daniel J, Duvic Madeleine, Golub Todd, Jones David A, Kupper Thomas S
Harvard Medical School, Boston, MA, USA.
Blood. 2007 Oct 15;110(8):3015-27. doi: 10.1182/blood-2006-12-061507. Epub 2007 Jul 16.
Cutaneous T-cell lymphoma (CTCL) is defined by infiltration of activated and malignant T cells in the skin. The clinical manifestations and prognosis in CTCL are highly variable. In this study, we hypothesized that gene expression analysis in lesional skin biopsies can improve understanding of the disease and its management. Based on 63 skin samples, we performed consensus clustering, revealing 3 patient clusters. Of these, 2 clusters tended to differentiate limited CTCL (stages IA and IB) from more extensive CTCL (stages IB and III). Stage IB patients appeared in both clusters, but those in the limited CTCL cluster were more responsive to treatment than those in the more extensive CTCL cluster. The third cluster was enriched in lymphocyte activation genes and was associated with a high proportion of tumor (stage IIB) lesions. Survival analysis revealed significant differences in event-free survival between clusters, with poorest survival seen in the activated lymphocyte cluster. Using supervised analysis, we further characterized genes significantly associated with lower-stage/treatment-responsive CTCL versus higher-stage/treatment-resistant CTCL. We conclude that transcriptional profiling of CTCL skin lesions reveals clinically relevant signatures, correlating with differences in survival and response to treatment. Additional prospective long-term studies to validate and refine these findings appear warranted.
皮肤T细胞淋巴瘤(CTCL)的定义是皮肤中存在活化的恶性T细胞浸润。CTCL的临床表现和预后差异很大。在本研究中,我们假设对病变皮肤活检进行基因表达分析可以增进对该疾病及其治疗的理解。基于63份皮肤样本,我们进行了一致性聚类分析,发现了3个患者聚类。其中,2个聚类倾向于将局限性CTCL(IA期和IB期)与更广泛的CTCL(IIB期和III期)区分开来。IB期患者出现在两个聚类中,但局限性CTCL聚类中的患者比更广泛CTCL聚类中的患者对治疗反应更好。第三个聚类富含淋巴细胞活化基因,并且与高比例的肿瘤(IIB期)病变相关。生存分析显示各聚类之间的无事件生存期存在显著差异,活化淋巴细胞聚类的生存期最差。通过监督分析,我们进一步对与低分期/治疗反应性CTCL和高分期/治疗抵抗性CTCL显著相关的基因进行了特征描述。我们得出结论,CTCL皮肤病变的转录谱分析揭示了与生存和治疗反应差异相关的临床相关特征。有必要开展更多前瞻性长期研究来验证和完善这些发现。